We know exercise is good for health, but there isn’t a one-size-fits-all prescription when it comes to individual needs. Everyone is different in terms of how their bodies fight diseases and respond to therapies. The physicians and scientists at AdventHealth are working on some of the biggest problems in health care, including uncovering the mystifying effects of exercise.
In this episode of the Inspiring Wholeness podcast, Dr. Steven Smith, senior vice president and chief scientific officer at AdventHealth and Bret Goodpaster, Ph.D., senior scientific director at AdventHealth’s Translational Research Institute, discuss partnering with the National Institute of Health on a 10-year study titled Molecular Transducers of Physical Activity Consortium (MoTrPAC).
The goal of the research is to discover more about why the body breaks; how physical activity can improve brain health, protect the heart, prevent diabetes, influence cancer and promote other health benefits; and why people’s bodies respond differently to exercise.
Listen now and subscribe so you never miss a new episode.
12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Celebration Team Performs First-in-World Procedure Targeting Kidney Tumor with Sound Beams
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
Podcast
Test Apple Podcast - All Episodes
Test Apple Podcast
Social Media Post
AdventHealthMD Social Media Post Test - Consumer Title
As the Official Healthcare Provider of the 2024 NASCAR Chicago Street Race, we’re thrilled to support such a memorable experience with this amazing community.
News
Clone of AdventHealth Celebration Team Performs First-in-world Procedure Targeting Kidney Tumor with Sound Beams
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Media Coverage
Consumer Title - AdventHealthMD Media Coverage Test
A summary of the article goes here. A summary of the article goes here. A summary of the article goes here. A summary of the article goes here.
News
AdventHealth Celebration Team Performs First-in-world Procedure Targeting Kidney Tumor with Sound Beams
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Video
Dr. Corbin on the gut microbiome research study
Dr. Corbin on the gut microbiome research study
News
Genetic Testing at AdventHealth Alerts Woman, Doctors to Aggressive Cancer Before it Develops
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
News
AdventHealth Clinical Research Unit Recruiting Patients with Solid Tumors Harboring MTAP Deletion for Phase I Clinical Trial
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
News
AdventHealth Research Institute conducting two studies on the impact of shift work on healthcare workers’ health
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
News
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...